Phosplatin Therapeutics is harnessing immunogenic cell death (ICD) as an alternative mechanism to existing cancer immunotherapy strategies. PT-112, Phosplatin’s lead ICD inducer, is in phase 2 ...
This special role allows the immune system to be educated by tasting healthy foods and the normal microbiota while keeping an eye out for dangerous invaders, preserving gut tolerance, and avoiding ...
Researchers evaluated the immunogenicity of hepatitis A virus vaccination as well as responses in patients with HIV and those on immunosuppressive therapy.